CA2361561A1 - Immunosurpressive effects of pteridine derivatives - Google Patents

Immunosurpressive effects of pteridine derivatives Download PDF

Info

Publication number
CA2361561A1
CA2361561A1 CA002361561A CA2361561A CA2361561A1 CA 2361561 A1 CA2361561 A1 CA 2361561A1 CA 002361561 A CA002361561 A CA 002361561A CA 2361561 A CA2361561 A CA 2361561A CA 2361561 A1 CA2361561 A1 CA 2361561A1
Authority
CA
Canada
Prior art keywords
dimethyl
dimethyllumazine
lumazine
pharmaceutical composition
meoh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361561A
Other languages
English (en)
French (fr)
Inventor
Mark Jozef Albert Waer
Piet Andre Maurits Maria Herdewijn
Wolfgang Eugen Pfleiderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4-AZA BIOSCIENCE NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2361561A1 publication Critical patent/CA2361561A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002361561A 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives Abandoned CA2361561A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11828299P 1999-02-02 1999-02-02
US11823599P 1999-02-02 1999-02-02
US11829599P 1999-02-02 1999-02-02
US60/118,282 1999-02-02
US60/118,295 1999-02-02
US60/118,235 1999-02-02
PCT/EP2000/000938 WO2000045800A2 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives

Publications (1)

Publication Number Publication Date
CA2361561A1 true CA2361561A1 (en) 2000-08-10

Family

ID=27382128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361561A Abandoned CA2361561A1 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives

Country Status (5)

Country Link
EP (1) EP1187615A2 (ja)
JP (1) JP2002536320A (ja)
AU (1) AU780284B2 (ja)
CA (1) CA2361561A1 (ja)
WO (1) WO2000045800A2 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
EE200200453A (et) 2000-02-16 2003-12-15 Neurogen Corporation Asendatud arüülpürasiinid
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
US7179807B2 (en) 2002-08-20 2007-02-20 Neurogen Corporation 5-substituted-2-arylpyrazines
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AU2004297235A1 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
ES2502527T3 (es) 2008-05-27 2014-10-03 Astrazeneca Ab Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados patológicos mediados por PDE4
EP3247361A4 (en) * 2015-01-22 2018-08-15 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
PT3321265T (pt) 2015-03-04 2020-07-07 Gilead Sciences Inc Compostos 4,6-diamino-pirido[3,2-d]pirimidina compounds e a sua utilização como moduladores de receptores do tipo toll
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
JP6746776B2 (ja) 2016-09-02 2020-08-26 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体調節剤化合物
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
KR20230034331A (ko) * 2020-07-03 2023-03-09 콤비타 리미티드 항-염증성 조성물, 이의 방법 및 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
WO1993025712A1 (en) * 1992-06-15 1993-12-23 The Regents Of The University Of California Screening assay for the identification of immunosuppressive drugs
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
WO1994014065A1 (en) * 1992-12-14 1994-06-23 Dana-Farber Cancer Institute, Inc. Methods for identifying and using immunosuppressant compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
EP0728003A1 (en) * 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5525711A (en) * 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
ATE220549T1 (de) * 1994-12-29 2002-08-15 Univ California Verbindungen zur hemmung der ceramid vermittelten signalübertragung
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
AU2666997A (en) * 1996-04-15 1997-11-07 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The In vitro prognostic test for progressors and non-progressors after hiv infection

Also Published As

Publication number Publication date
WO2000045800A2 (en) 2000-08-10
WO2000045800A3 (en) 2002-01-10
EP1187615A2 (en) 2002-03-20
JP2002536320A (ja) 2002-10-29
AU780284B2 (en) 2005-03-10
AU2441800A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
AU780284B2 (en) Immunosurpressive effects of pteridine derivatives
EP0956855B1 (en) Immunosuppressive effects of 8 substituted xanthine derivatives
US6946465B2 (en) Immunosuppressive effects of pteridine derivatives
Allison Immunosuppressive drugs: the first 50 years and a glance forward
EP1144412B1 (en) Immunosuppressive effects of pteridine derivatives
CN101084227B (zh) 雷帕霉素类似物及其治疗神经紊乱、增殖性和炎性疾病的用途
HU228369B1 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
US6046328A (en) Combination preparation, containing cyclosporin A or FK506 or rapamycin and a xanthine derivative
JPH04244087A (ja) 水素添加ラパマイシン誘導体
CN105517553B (zh) 基于吡唑并[1,5-a]嘧啶的化合物、包含其的组合物和其使用方法
JPH11508570A (ja) ピロロピリミジン類およびその製造方法
BG106695A (bg) 2,4-диаминопиримидинови съединения, полезни като антисупресанти
JP2021518344A (ja) Ａｔｒキナーゼの複素環式阻害剤
CA2939286A1 (en) Spirocyclic containing compounds and pharmaceutical uses thereof
JP3464230B2 (ja) ピリダジンジオン化合物、該化合物を含有する神経障害を治療するための医薬組成物、動物の神経障害を治療する方法、及び該化合物の製造方法
WO1996004906A1 (en) Compounds for the treatment of restenosis
JPH08512281A (ja) アデノシンａ▲下１▼受容体拮抗剤としてのキサンチン誘導体類
EP0901476A1 (en) Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
Argyropoulos et al. Immunosuppressive drugs in HIV disease
US7253176B1 (en) Immunosuppressive effects of 8-substituted xanthine derivatives
EP0545413B1 (en) Trans cyclopentanyl purine analogs useful as immunosuppressants
AU757489B2 (en) Method for inhibiting cytokine production by cells
CA2519026A1 (en) Therapeutic and/or preventive agent for chronic skin disease
JP2000086511A (ja) フェニルチアゾール骨格を有するプリンまたはピリミジンヌクレオシド取り込み阻害剤
JPH06508120A (ja) ベンゾジアゼピンレセプターのリガンドとして６−アザインドール類から誘導された化合物とそれらを含有した薬剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued